Zusammengesetzter Bewertungsbereich · konservativ €24–€26 / fair €29–€41 / optimistisch €47–€54. Bei €24.94, Innerhalb des konservativen Bereichs des inneren Werts · erhebliche Sicherheitsmarge.
Bei Veröffentlichung €27.96 (26. Juni 2026)
Carl Zeiss Meditec appointed Bronwyn Brophy O'Connor as CEO, succeeding Maximilian Foerst after his code-of-conduct departure.
Possible impact:May affect investor expectations for governance stability and execution of the turnaround plan.
Carl Zeiss Meditec announced a cost program affecting up to 1,000 jobs and guided FY revenue to EUR 2.15-2.20 billion.
Possible impact:May affect expectations for China headwinds, margin recovery timing and execution of planned savings.
Automatically summarized from public sources; for context only, not investment advice.
Daten von EODHD, dargestellt in der Berichtswährung; nur zu Informationszwecken, keine Anlageberatung.
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and phacoemulsification and vitrectomy equipment; intraocular lenses for cataract surgery; and systems and consumables for laser eye surgery that include the VISUMAX femtosecond laser, which enables minimally invasive correction of vision defects using lenticular extraction, as well as digital products for the storage, analysis, and sharing of clinical data. The Microsurgery segment provides products and solutions for minimally invasive surgical treatments, including surgical visualization, interoperative radiotherapy, interoperative pathology, special surgical instruments, and digital solutions, as well as the ZEISS Tumor Workflow, a cross-product workflow solution. It serves physicians in various fields and hospitals. The company has a strategic collaboration with Envision Health Technologies Inc. to help advance glaucoma care through gamified virtual reality technology. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG operates as a subsidiary of ZEISS Group.
DemnächstDieser Abschnitt wird gerade ergänzt — schauen Sie bald wieder vorbei.
DemnächstDieser Abschnitt wird gerade ergänzt — schauen Sie bald wieder vorbei.
Noch keine Analysen zu dieser Aktie in Ihrer Sprache.
